Literature DB >> 22327204

Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -/- mice.

Elizabeth P Newberry1, Susan M Kennedy, Yan Xie, Jianyang Luo, Rosanne M Crooke, Mark J Graham, Jin Fu, Daniele Piomelli, Nicholas O Davidson.   

Abstract

The tissue-specific sources and regulated production of physiological signals that modulate food intake are incompletely understood. Previous work showed that L-Fabp(-/-) mice are protected against obesity and hepatic steatosis induced by a high-fat diet, findings at odds with an apparent obesity phenotype in a distinct line of aged L-Fabp(-/-) mice. Here we show that the lean phenotype in L-Fabp(-/-) mice is recapitulated in aged, chow-fed mice and correlates with alterations in hepatic, but not intestinal, fatty acid amide metabolism. L-Fabp(-/-) mice exhibited short-term changes in feeding behavior with decreased food intake, which was associated with reduced abundance of key signaling fatty acid ethanolamides, including oleoylethanolamide (OEA, an agonist of PPARα) and anandamide (AEA, an agonist of cannabinoid receptors), in the liver. These reductions were associated with increased expression and activity of hepatic fatty acid amide hydrolase-1, the enzyme that degrades both OEA and AEA. Moreover, L-Fabp(-/-) mice demonstrated attenuated responses to OEA administration, which was completely reversed with an enhanced response after administration of a nonhydrolyzable OEA analog. These findings demonstrate a role for L-Fabp in attenuating obesity and hepatic steatosis, and they suggest that hepatic fatty acid amide metabolism is altered in L-Fabp(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22327204      PMCID: PMC3307651          DOI: 10.1194/jlr.M020966

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  34 in total

1.  Fatty acid amide hydrolase determines anandamide-induced cell death in the liver.

Authors:  Sören V Siegmund; Ekihiro Seki; Yosuke Osawa; Hiroshi Uchinami; Benjamin F Cravatt; Robert F Schwabe
Journal:  J Biol Chem       Date:  2006-01-17       Impact factor: 5.157

2.  Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339.

Authors:  John S Millar; Debra A Cromley; Mary G McCoy; Daniel J Rader; Jeffrey T Billheimer
Journal:  J Lipid Res       Date:  2005-07-01       Impact factor: 5.922

3.  Alms1-disrupted mice recapitulate human Alström syndrome.

Authors:  G B Collin; E Cyr; R Bronson; J D Marshall; E J Gifford; W Hicks; S A Murray; Q Y Zheng; R S Smith; P M Nishina; J K Naggert
Journal:  Hum Mol Genet       Date:  2005-07-06       Impact factor: 6.150

4.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.

Authors:  Douglas Osei-Hyiaman; Michael DePetrillo; Pál Pacher; Jie Liu; Svetlana Radaeva; Sándor Bátkai; Judith Harvey-White; Ken Mackie; László Offertáler; Lei Wang; George Kunos
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

5.  Effect of chronic caloric restriction on the circadian regulation of physiological and behavioral variables in old male B6C3F1 mice.

Authors:  P H Duffy; R J Feuers; R W Hart
Journal:  Chronobiol Int       Date:  1990       Impact factor: 2.877

6.  Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.

Authors:  Jin Fu; Fariba Oveisi; Silvana Gaetani; Edward Lin; Daniele Piomelli
Journal:  Neuropharmacology       Date:  2005-04-21       Impact factor: 5.250

7.  Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice.

Authors:  Todor Arsov; Claire Z Larter; Christopher J Nolan; Nikolai Petrovsky; Christopher C Goodnow; Narcissus C Teoh; Matthew M Yeh; Geoffrey C Farrell
Journal:  Biochem Biophys Res Commun       Date:  2006-02-20       Impact factor: 3.575

8.  Fat aussie--a new Alström syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis.

Authors:  Todor Arsov; Diego G Silva; Moira K O'Bryan; Amanda Sainsbury; Nicola J Lee; Claire Kennedy; Shehnaaz S M Manji; Keats Nelms; Conan Liu; Carola G Vinuesa; David M de Kretser; Christopher C Goodnow; Nikolai Petrovsky
Journal:  Mol Endocrinol       Date:  2006-03-02

9.  Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene.

Authors:  Elizabeth P Newberry; Yan Xie; Susan Kennedy; Xianlin Han; Kimberly K Buhman; Jianyang Luo; Richard W Gross; Nicholas O Davidson
Journal:  J Biol Chem       Date:  2003-10-08       Impact factor: 5.157

10.  Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha.

Authors:  Jin Fu; Silvana Gaetani; Fariba Oveisi; Jesse Lo Verme; Antonia Serrano; Fernando Rodríguez De Fonseca; Anja Rosengarth; Hartmut Luecke; Barbara Di Giacomo; Giorgio Tarzia; Daniele Piomelli
Journal:  Nature       Date:  2003-09-04       Impact factor: 49.962

View more
  19 in total

1.  Direct comparison of mice null for liver or intestinal fatty acid-binding proteins reveals highly divergent phenotypic responses to high fat feeding.

Authors:  Angela M Gajda; Yin Xiu Zhou; Luis B Agellon; Susan K Fried; Sarala Kodukula; Walter Fortson; Khamoshi Patel; Judith Storch
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

2.  Hepatic ATGL mediates PPAR-α signaling and fatty acid channeling through an L-FABP independent mechanism.

Authors:  Kuok Teong Ong; Mara T Mashek; Nicholas O Davidson; Douglas G Mashek
Journal:  J Lipid Res       Date:  2014-03-08       Impact factor: 5.922

Review 3.  Enterocyte fatty acid-binding proteins (FABPs): different functions of liver and intestinal FABPs in the intestine.

Authors:  Angela M Gajda; Judith Storch
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-10-14       Impact factor: 4.006

4.  Changes in FABP1 and gastrin receptor expression in the testes of rats that have undergone electrical injury.

Authors:  Xue-Fang Li; Quan-Yong Huang; Shui-Ping Liu
Journal:  Exp Ther Med       Date:  2015-03-23       Impact factor: 2.447

5.  Serum FABP1 Levels Correlate Positively with Obesity in Chinese Patients After Laparoscopic Sleeve Gastrectomy: a 12-Month Follow-up Study.

Authors:  Hui You; Xin Wen; Cuiling Zhu; Ming Chen; Liting Dong; Yanli Zhu; Liu Yang; Le Bu; Manna Zhang; Donglei Zhou; Liesheng Lu; Lei Du; Ziwei Lin; Shen Qu
Journal:  Obes Surg       Date:  2020-03       Impact factor: 4.129

6.  Liver fatty acid-binding protein (L-Fabp) modifies intestinal fatty acid composition and adenoma formation in ApcMin/+ mice.

Authors:  Sekhar Dharmarajan; Elizabeth P Newberry; Grace Montenegro; Ilke Nalbantoglu; Victoria R Davis; Michael J Clanahan; Valerie Blanc; Yan Xie; Jianyang Luo; James W Fleshman; Susan Kennedy; Nicholas O Davidson
Journal:  Cancer Prev Res (Phila)       Date:  2013-08-06

7.  Impact of SCP-2/SCP-x gene ablation and dietary cholesterol on hepatic lipid accumulation.

Authors:  Devon Klipsic; Danilo Landrock; Gregory G Martin; Avery L McIntosh; Kerstin K Landrock; John T Mackie; Friedhelm Schroeder; Ann B Kier
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-06-25       Impact factor: 4.052

8.  Liver fatty acid binding protein gene-ablation exacerbates weight gain in high-fat fed female mice.

Authors:  Avery L McIntosh; Barbara P Atshaves; Danilo Landrock; Kerstin K Landrock; Gregory G Martin; Stephen M Storey; Ann B Kier; Friedhelm Schroeder
Journal:  Lipids       Date:  2013-03-29       Impact factor: 1.880

9.  Phenotypic divergence in two lines of L-Fabp-/- mice reflects substrain differences and environmental modifiers.

Authors:  Elizabeth P Newberry; Susan Kennedy; Yan Xie; Jianyang Luo; Hui Jiang; Daniel S Ory; Nicholas O Davidson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-08-06       Impact factor: 4.052

10.  Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease.

Authors:  Anping Chen; Youcai Tang; Victoria Davis; Fong-Fu Hsu; Susan M Kennedy; Haowei Song; John Turk; Elizabeth M Brunt; Elizabeth P Newberry; Nicholas O Davidson
Journal:  Hepatology       Date:  2013-05-15       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.